Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer

Annals of Oncology

Volumn 7, Issue 8, 1996, Pages 861-863

  Lissoni, A ^a   Zanetta, G ^a,b   Losa, G ^a   Gabriele, A ^a   Parma, G ^a   Mangioni, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Cisplatin; Endometrial cancer; Paclitaxel; Survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL;

EID: 0029906477     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010768     Document Type: Article

References (12)

1. Wingo PA, Tong T, Bolden S. Cancer Stat 1995; 45(1): 8-30.
2. Moore TD, Phillips PH, Nerenstone SR, Cheson BD. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions. J Clin Oncol 1991; 9: 1071-88.
3. Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol 1994; 21: 107-13.
4. Thigpen T, Blessing J, Homesley H et al. Phase III trial of doxorubicin +/- cisplatin in advanced or recurrent endometrial carcinoma; a gynecologic oncology group (GOG) study. Proc Am Soc Clin Oncol 1993; 12: 261.
5. Turbow MM, Ballon SC, Sikic BI, Koretz MM. Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma. Cancer Treat Rep 1985; 69: 465-9.
6. Hancock KC, Freedman RS, Edwards CL, Rutledge FN. Use of cisplatin, doxorubicin and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium. Cancer Treat Rep 1986; 70: 789-91.
7. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 1989; 111: 273-9.
8. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecological Oncology Group Study. J Clin Oncol 1994; 12: 1748-53.
9. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paelitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
10. Thigpen T, Vance RB, Khansur T. The platinum compounds and paelitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995; 22 (Suppl 12): 67-75.
11. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer. A critical need for precise definition of the treated population. J Clin Oncol 1992; 10: 513-4.
12. Miller AB, Hoogstraten B, Staquet H, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.